Cantor Fitzgerald Predicts AQST FY2026 Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Aquestive Therapeutics in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska anticipates that the company will earn ($0.81) per share for the year. The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.07). The firm had revenue of $8.72 million for the quarter, compared to the consensus estimate of $12.23 million.

Several other research firms have also weighed in on AQST. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research report on Thursday, May 15th. Raymond James set a $7.00 target price on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Lake Street Capital lowered their price target on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, March 7th. Alliance Global Partners reaffirmed a “buy” rating on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Finally, Oppenheimer assumed coverage on Aquestive Therapeutics in a research report on Monday, June 2nd. They set an “outperform” rating and a $7.00 price objective for the company. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $10.14.

Aquestive Therapeutics Stock Up 1.0%

Shares of NASDAQ AQST opened at $3.58 on Wednesday. Aquestive Therapeutics has a 52-week low of $2.12 and a 52-week high of $5.80. The stock has a market capitalization of $355.20 million, a price-to-earnings ratio of -7.96 and a beta of 1.94. The stock’s fifty day simple moving average is $2.71 and its 200 day simple moving average is $3.11.

Hedge Funds Weigh In On Aquestive Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in Aquestive Therapeutics by 1.9% during the fourth quarter. Vanguard Group Inc. now owns 4,346,754 shares of the company’s stock worth $15,474,000 after purchasing an additional 82,958 shares during the period. Pale Fire Capital SE increased its holdings in Aquestive Therapeutics by 154.1% in the 1st quarter. Pale Fire Capital SE now owns 1,335,684 shares of the company’s stock valued at $3,873,000 after buying an additional 809,928 shares during the period. Janney Montgomery Scott LLC raised its stake in shares of Aquestive Therapeutics by 7.6% in the 1st quarter. Janney Montgomery Scott LLC now owns 1,059,760 shares of the company’s stock valued at $3,073,000 after buying an additional 75,275 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Aquestive Therapeutics by 905.2% during the 4th quarter. Bank of America Corp DE now owns 690,284 shares of the company’s stock worth $2,457,000 after acquiring an additional 621,614 shares during the period. Finally, Northern Trust Corp boosted its position in shares of Aquestive Therapeutics by 3.1% during the 4th quarter. Northern Trust Corp now owns 599,812 shares of the company’s stock valued at $2,135,000 after acquiring an additional 18,199 shares in the last quarter. 32.45% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.